PRTK Stock Overview
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.
Paratek Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.07|
|52 Week High||US$11.24|
|52 Week Low||US$4.03|
|1 Month Change||-21.73%|
|3 Month Change||-26.53%|
|1 Year Change||-39.16%|
|3 Year Change||-43.24%|
|5 Year Change||-69.51%|
|Change since IPO||-74.56%|
Recent News & Updates
The Play On Paratek Pharmaceuticals
Today, we take a quick look back at antibiotic concern Paratek Pharmaceuticals. While I am very underweight the antibiotic space due to the terrible economics there, Paratek has some unique features that make the stock one I own. An analysis and how I am positioned in Paratek Pharmaceuticals follows in the paragraphs below.
|PRTK||US Pharmaceuticals||US Market|
Return vs Industry: PRTK underperformed the US Pharmaceuticals industry which returned 12.6% over the past year.
Return vs Market: PRTK underperformed the US Market which returned 17.8% over the past year.
|PRTK Average Weekly Movement||5.8%|
|Pharmaceuticals Industry Average Movement||9.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: PRTK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: PRTK's weekly volatility (6%) has been stable over the past year.
About the Company
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.
Paratek Pharmaceuticals Fundamentals Summary
|PRTK fundamental statistics|
Is PRTK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PRTK income statement (TTM)|
|Cost of Revenue||US$46.01m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.03|
|Net Profit Margin||-45.32%|
How did PRTK perform over the long term?See historical performance and comparison
Is Paratek Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Paratek Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Paratek Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Paratek Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRTK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: PRTK is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PRTK's is expected to become profitable in the next 3 years.
Revenue vs Market: PRTK's revenue (27.9% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: PRTK's revenue (27.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRTK's Return on Equity is forecast to be high in 3 years time
How has Paratek Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRTK is currently unprofitable.
Growing Profit Margin: PRTK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PRTK is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare PRTK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRTK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: PRTK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Paratek Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PRTK has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PRTK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRTK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PRTK has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 7% each year.
What is Paratek Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PRTK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PRTK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PRTK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRTK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PRTK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Evan Loh (62 yo)
Dr. Evan Loh, M.D., FACC, FAHA, serves as Independent Director at Windtree Therapeutics, Inc. since February 2021. Dr. Loh has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 2...
CEO Compensation Analysis
Compensation vs Market: Evan's total compensation ($USD1.53M) is above average for companies of similar size in the US market ($USD1.13M).
Compensation vs Earnings: Evan's compensation has been consistent with company performance over the past year.
Experienced Management: PRTK's management team is considered experienced (2.5 years average tenure).
Experienced Board: PRTK's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.
Paratek Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Paratek Pharmaceuticals, Inc.
- Ticker: PRTK
- Exchange: NasdaqGM
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$211.797m
- Shares outstanding: 50.19m
- Website: https://paratekpharma.com
Number of Employees
- Paratek Pharmaceuticals, Inc.
- 75 Park Plaza
- 4th Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/02 00:01|
|End of Day Share Price||2021/12/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.